Search research articles
Contact Us
Filters
Showing results (211-220 of 221) with videos related to
Page
of 23
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 23, 2024
Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer
Pradeep S Chauhan, Irfan Alahi, Savar Sinha, et al.
Cancer Immunology Research
|
October 30, 2019
Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses
James W Welsh, Chad Tang, Patricia de Groot, et al.
European Urology
|
August 1, 2025
Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND Trial
Alexander D Sherry, Bilal A Siddiqui, Cara Haymaker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2024
Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial
Ethan B Ludmir, Alexander D Sherry, Bryan M Fellman, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
July 8, 2021
High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial
Roshal R Patel, Kewen He, Hampartsoum B Barsoumian, et al.
European Urology
|
March 15, 2026
A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy Versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer
Brian F Chapin, Marc Smaldone, Amado J Zurita, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 7, 2025
Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial
Jarey H Wang, Alexander D Sherry, Soha Bazyar, et al.
Urologic Oncology
|
August 17, 2025
Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank
Daniel D Shapiro, Edwin Jason Abel, Laurence Albiges, et al.
Genome Biology
|
November 5, 2020
Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity
Won-Chul Lee, Alexandre Reuben, Xin Hu, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 28, 2012
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
Stephen B Willingham, Jens-Peter Volkmer, Andrew J Gentles, et al.
Page
of 23
Search research articles
Search
Showing results (211-220 of 221) with videos related to
Sort By:
Page
of 23
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 23, 2024
Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer
Pradeep S Chauhan, Irfan Alahi, Savar Sinha, et al.
Cancer Immunology Research
|
October 30, 2019
Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses
James W Welsh, Chad Tang, Patricia de Groot, et al.
European Urology
|
August 1, 2025
Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND Trial
Alexander D Sherry, Bilal A Siddiqui, Cara Haymaker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2024
Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial
Ethan B Ludmir, Alexander D Sherry, Bryan M Fellman, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
July 8, 2021
High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial
Roshal R Patel, Kewen He, Hampartsoum B Barsoumian, et al.
European Urology
|
March 15, 2026
A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy Versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer
Brian F Chapin, Marc Smaldone, Amado J Zurita, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 7, 2025
Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial
Jarey H Wang, Alexander D Sherry, Soha Bazyar, et al.
Urologic Oncology
|
August 17, 2025
Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank
Daniel D Shapiro, Edwin Jason Abel, Laurence Albiges, et al.
Genome Biology
|
November 5, 2020
Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity
Won-Chul Lee, Alexandre Reuben, Xin Hu, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 28, 2012
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
Stephen B Willingham, Jens-Peter Volkmer, Andrew J Gentles, et al.
Page
of 23